BRD9 and acute myeloid leukemia: Specifically, we identified two VHL‐based PROTACs (2 and 9) based on a [1,2,4]triazolo[4,3‐a]quinoxaline scaffold that effectively and selectively degrade BRD9 and exhibit antiproliferative effects in acute myeloid leukemia (AML) cells, offering potential strategies for AML treatment and insights into BRD9's role in tumors.